What's Happening?
A new oral drug, TLC-12716, has been found to safely lower triglycerides and other blood lipids, according to a clinical trial conducted by scientists at EPFL and OrsoBio. The drug targets the Liver X Receptor (LXR) specifically in the liver and gut,
reducing triglycerides without affecting protective cholesterol pathways. The trial, published in Nature Medicine, demonstrated that the drug could lower triglycerides by up to 38.5% and remnant cholesterol by 61% in healthy adults. This development offers a potential new treatment for metabolic diseases associated with high triglycerides.
Why It's Important?
The discovery of TLC-12716 is significant as it addresses the challenge of managing high triglycerides, a condition linked to increased risks of heart disease, stroke, and pancreatitis. Current treatments often have side effects due to their broad impact on cholesterol pathways. By specifically targeting LXR in the liver and gut, TLC-12716 offers a more focused approach, potentially reducing side effects and improving patient outcomes. This advancement could lead to new therapeutic options for individuals with hypertriglyceridemia and related metabolic disorders.
What's Next?
Following the successful Phase I trial, further clinical testing in Phase II studies is anticipated. These studies will likely involve individuals with hypertriglyceridemia and metabolic dysfunction-associated steatotic liver disease (MASLD). If successful, TLC-12716 could become a key component in the treatment of metabolic diseases, offering a new avenue for managing high triglycerides. The ongoing research will focus on confirming the drug's efficacy and safety in larger, more diverse populations.
